Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER_GOV 1OTHER 1NETWORK 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Multiple Myeloma 1Lung Neoplasms 1Leukemia, Biphenotypic, Acute 1Carcinoma, Non-Small-Cell Lung 1Burkitt Lymphoma 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1

Interventions

Vincristine 17Cyclophosphamide 17Cytarabine 16Methotrexate 14Doxorubicin 14Prednisone 11Etoposide 11Radiotherapy 10merphos 9Rituximab 8Dexamethasone 8pegaspargase 7Leucovorin 7Filgrastim 7Calcium Dobesilate 7Methylprednisolone 6Daunorubicin 6dexamethasone acetate 5dexamethasone 21-phosphate 5calaspargase pegol 5azathiopurine 5auricularum 5Thioguanine 5Mercaptopurine 5Hydrocortisone 5Granulocyte Colony-Stimulating Factor 5Asparaginase 5prednylidene 4deltacortene 4Specimen Handling 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Burkitt Lymphoma × Injections × Clear all
NCT05320380 2023-09-01

A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat

Children's Oncology Group

Phase 1/2 Withdrawn
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡